First-in-Human Study of STX-478, a Mutant Selective PI3K alpha Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
![Photograph of Anthony Elias](https://som.ucdenver.edu/FIMS/Content/faculty/872/CU-Doctors-872.jpg)
Anthony Elias
Study ID
Protocol Number: 23-0200
More information available at ClinicalTrials.gov: NCT05768139
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers